Wei AH, et al. - In adults (60 years or older) with previously untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy, researchers assessed the safety and preliminary effectiveness of venetoclax (a selective B-cell leukemia/lymphoma-2 inhibitor) combined with low-dose cytarabine (LDAC) in an international phase Ib/II study. The recommended phase II dose was venetoclax 600 mg per day orally in 28-day cycles, with LDAC (20 mg/m² per day) administered subcutaneously on days 1 to 10. This dose was used to treat 82 patients. Findings revealed a manageable safety profile of venetoclax plus LDAC. Furthermore, rapid and durable remissions were offered by treatment with venetoclax plus LDAC in older adults with AML ineligible for intensive chemotherapy. For these patients, venetoclax and LDAC represents an attractive and new treatment option by providing a high remission rate and low early mortality combined with rapid and durable remission.